Aligos Therapeutics Plunges 15.97% on Disappointing Earnings

On April 7, 2025, Aligos Therapeutics, Inc. (ALGS) experienced a significant drop of 15.97% in pre-market trading, marking a notable decline in its stock performance.

Aligos Therapeutics recently reported its fourth-quarter financial results, which included a loss and revenue that fell short of analysts' estimates. This disappointing performance likely contributed to the recent decline in the company's stock price.

In a positive development, Aligos Therapeutics presented encouraging data at the APASL 2025 conference. This presentation highlighted the company's progress in its research and development efforts, which could potentially boost investor confidence in the long term.